Olaratumab

From WikiMD

Revision as of 17:31, 19 April 2019 by Prab (talk | contribs) (Created page with "{{intro}}Olaratumab is a human monoclonal antibody to the platelet-derived growth factor (PDGF) receptor alpha and an antineoplastic agent used in the therapy of advanced ...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

== Information about Olaratumab ==Olaratumab is a human monoclonal antibody to the platelet-derived growth factor (PDGF) receptor alpha and an antineoplastic agent used in the therapy of advanced soft tissue sarcoma

Liver safety of Olaratumab

Olaratumab has not been linked to serum enzyme elevations during therapy or to idiosyncratic acute liver injury

Mechanism of action of Olaratumab

Olaratumab (oh" lar at' ue mab) is a recombinant human monoclonal IgG1 antibody to the platelet-derived growth factor receptor alpha.  Signaling through PDGF receptors promotes cell proliferation and angiogenesis.  Inhibition of the PDGF signaling decreases formation of new blood vessels, which plays an important role in growth and spread of cancer cells.  When used in combination with other antineoplastic agents, olaratumab has been shown to extend recurrence-free survival in several forms of advanced cancer. 

FDA approval information for Olaratumab

Olaratumab was approved in the United States in 2016 for use in combination with doxorubicin for refractory, advanced soft tissue sarcoma

Dosage and administration for Olaratumab

Olaratumab is available in solution in single use vials of 500 mg in 50 mL or 190 mg in 19 mL (10 mg/mL) under the brand name Lartruvo.  The typical dose is 15 mg/kg intravenously over 60 minutes on days 1 and 8 of each 21-day cycle.  Premedication with diphenhydramine and dexamethasone is recommended with the initial dose. 

Side effects of Olaratumab

Olaratumab is administered with doxorubicin and this combination has significant adverse side effects, including nausea and vomiting, diarrhea, fatigue, anorexia, abdominal pain, alopecia, peripheral neuropathy, neutropenia, and stomatitis.  Uncommon, but potentially severe adverse events include severe infusion reactions, hypersensitivity reactions, and embryofetal toxicity.   

 


The article on Olaratumab is a stub. YOU can help Wikimd by expanding it!

Medication resources

Learn more


edit 

About WikiMD

About us: WikiMD is a free medical encyclopedia and wellnesspedia moderated by medical professionals.

Our mission: Provide up to date physician reviewed health, nutrition and wellness information for free in over 100 languages.

Join us: This article is a stub. Help improve Olaratumab or others. Do not trust amateurs with your life! Join us in this effort!. Paid editors welcome.

Pubmed.png Uptodate.png Wikipedia Reddit YouTube videos
W8MD weight loss logo

Ad. Tired of being overweight?. W8MD's insurance Weight loss program can HELP*

Quick links: Medicine Portal | Encyclopedia‏‎‏‎ | Gray's Anatomy‏‎ | Topics‏‎ |‏‎ Diseases‏‎ | Drugs | Wellness | Obesity‏‎ | Metabolic syndrome | Weight loss*
Disclaimer: The entire contents of WIKIMD.ORG are for informational purposes only and do not render medical advice or professional services. If you have a medical emergency, you should CALL 911 immediately! Given the nature of the wiki, the information provided may not be accurate, misleading and or incorrect. Use the information on this wiki at your own risk! See full Disclaimer.
Link to this page: <a href="http://www.wikimd.org/wiki/Olaratumab">Olaratumab</a>

  • Individual results may vary for weight loss from our sponsors.